Clinical course and outcomes of MDR-TB treatment, by HIV status.^a

a<p>Table values are median (IQR) for continuous variables and n (column %) for categorical variables.</p>b<p>Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.</p>c<p>P-value is for Wilcoxon rank sum test (continuous variables) or Fisher’s exact test (categorical variables).</p>d<p>Calculated among those who completed the intensive phase of treatment.</p>e<p>Calculated among those who had positive results at baseline (within one month before or one week after initiation of MDR-TB treatment).</p

Univariate, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.

1<p>Continuous variable, mean (standard deviation) presented.</p>2<p><18.5 in women; <20 in men; or malnutrition established clinically.</p>3<p>≤30% in women; ≤36% in men; when missing, also used hemoglobin ≤10 in women and ≤12 in men.</p>4<p>Dyspnea; resting respiratory rate greater than 26/minute.</p>5<p>Resistance to the following 12 drugs or drug classes was tested: capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin or amikacin, PAS, pyrazinamide, rifampicin, streptomycin, first-generation fluoroquinolones (ciprofloxacin, ofloxacin), and later-generation fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin).</p>6<p>Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin, or amikacin).</p>7<p>This includes the following comorbidities: cardiovascular disease (12), diabetes mellitus (18), hepatitis or cirrhosis (10), epilepsy/seizures (11), renal insufficiency (7), psychiatric disorder (116), ever smoked (66), ever used/abused alcohol or other substance (52).</p

Distribution of covariates at initiation of ITR.

1<p>Continuous variable, mean (standard deviation) presented.</p>2<p><18.5 in women; <20 in men; or malnutrition established clinically.</p>3<p>≤30% in women; ≤36% in men; when missing, also used hemoglobin ≤10 in women and ≤12 in men.</p>4<p>Dyspnea; resting respiratory rate greater than 26/minute.</p>5<p>Resistance to the following 12 drugs or drug classes was tested: capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin or amikacin, PAS, pyrazinamide, rifampicin, streptomycin, first-generation fluoroquinolones (ciprofloxacin, ofloxacin), and later-generation fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin).</p>6<p>Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin, or amikacin).</p>7<p>This includes the following comorbidities: cardiovascular disease (12), diabetes mellitus (18), hepatitis or cirrhosis (10), epilepsy/seizures (11), renal insufficiency (7), psychiatric disorder (116), ever smoked (66), ever used/abused alcohol or other substance (52).</p

Multivariable, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.

<p>Multivariable, time-varying Cox proportional hazards analysis of aggressive regimen and time to death.</p

Treatment outcomes of 669 patients enrolled in individualized treatment for MDR-TB in Peru between February 1999 and July 2002. (Adapted from Mitnick et al., 2008) [20].

<p>Treatment outcomes of 669 patients enrolled in individualized treatment for MDR-TB in Peru between February 1999 and July 2002. (Adapted from Mitnick et al., 2008) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058664#pone.0058664-Mitnick2" target="_blank">[20]</a>.</p